<DOC>
	<DOCNO>NCT00008060</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy effective advanced colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness fluorouracil combine leucovorin either irinotecan oxaliplatin treat patient unresectable metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Unresectable Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy combination chemotherapy comprise fluorouracil ( 5-FU ) leucovorin calcium ( CF ) either irinotecan ( CPT-11 ) oxaliplatin vs standard sequential single-agent therapy comprise 5-FU CF follow CPT-11 patient unresectable metastatic colorectal cancer . - Determine whether combination chemotherapy best use first-line therapy reserve second-line therapy progression first-line single-agent therapy patient . - Compare efficacy toxicity irinotecan-containing regimen v oxaliplatin-containing regimen patient . - Compare overall survival , progression-free survival , quality life patient treat regimen . - Compare safety toxicity regimens patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize one five treatment arm . - Arm I ( standard therapy ) : Patients receive first-line chemotherapy comprise leucovorin calcium IV 2 hour day 1 follow fluorouracil IV continuously 46 hour day 1-2 every 14 day . Patients progressive disease receive second-line therapy comprise irinotecan IV 90 minute day 1 every 21 day . - Arm II : Patients receive first-line chemotherapy arm I . Patients progressive disease receive second-line therapy comprise irinotecan IV 30 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1-2 every 14 day . - Arm III : Patients receive first-line chemotherapy comprise irinotecan , leucovorin calcium , fluorouracil second-line therapy arm II . - Arm IV : Patients receive first-line chemotherapy arm I . Patients progressive disease receive second-line therapy comprise leucovorin calcium IV oxaliplatin IV 2 hour day 1 follow fluorouracil IV continuously 46 hour day 1-2 every 14 day . - Arm V : Patients receive first-line chemotherapy comprise leucovorin calcium , oxaliplatin , fluorouracil second-line therapy arm IV . Treatment continue arm absence disease progression unacceptable toxicity . Quality life assess baseline , week 6 12 , every 12 week thereafter . PROJECTED ACCRUAL : A total 2,100 patient ( 700 arm I 350 arm II-V ) accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma colon rectum Unresectable disease Measurable evaluable disease No partial complete bowel obstruction PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 150,000/mm^3 Hepatic : Bilirubin le 1.25 time upper limit normal ( ULN ) Alkaline phosphatase less 5 time ULN AST ALT less 3 time ULN No Gilbert 's syndrome congenital abnormality biliary transport ( e.g. , CriglerNajjar syndrome DubinJohnson syndrome ) Renal : Creatinine clearance great 50 mL/min OR Glomerular filtration rate normal Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No uncontrolled medical illness No prior concurrent malignancy would preclude study entry No chronic diarrhea inflammatory bowel disease No grade 2 great preexisting neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior adjuvant chemotherapy Prior adjuvant fluorouracil allow No prior chemotherapy metastatic disease No prior oxaliplatin irinotecan Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : No prior transplantation surgery require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>